Renal Dose Adjustment (Based on CrCl)
- 30-80 mL/min: No dose adjustments
- 30 mL/min: Start 0.5 mg PO daily, may be titrated to max 0.5 mg PO bid
- Hemodialysis: Max 0.5 mg PO daily. No supplement
Hepatic Dose Adjustment
- Hepatic impairment: No dose adjustments
See Supplemental Patient Information
- Approved for use only in adults (
18 yrs) - Serious neuropsychiatric symptoms in patients with or without preexisting psychiatric disease have occurred; discontinue if symptoms such as changes in behavior, suicidal ideation, agitation, depressed mood, or behavior occur [US Black Box Warning]
- Patients who discontinue treatment due to neuropsychiatric events should continue to be monitored until symptoms resolve
- Post-marketing reports of hypersensitivity reactions including angioedema
- Serious skin reactions, including Stevens-Johnson Syndrome and erythema multiforme may occur
- Cardiovascular events such as angina pectoris, nonfatal MI, nonfatal stroke has been reported when used in patients with stable cardiovascular disease
- Serious cardiovascular events such as nonfatal myocardial infarction, need for coronary revascularization, angina pectoris, transient ischemic attack, peripheral vascular disease have been reported during non-treatment follow up to 52 weeks. Varenicline has not been studied in patients with unstable cardiovascular disease
- May affect performance of skilled tasks
- Dose-dependent transient and persistent nausea may occur; reduce dosage
- Monitor for signs of suicidal ideation or behavior, or changes in behavior
- Monitor Cr at baseline
Cautions: Use cautiously in
- Renal impairment (refer dose adjustment section)
- Hx of psychiatric disorder
- Angioedema
Supplemental Patient Information
- Advise caregivers to monitor patients for symptoms of suicidal ideation or suicidal behavior, agitation, hostility, depressed mood, or changes in behavior
- Instruct patient to set a date to quit smoking and start varenicline 1 wk before the quit date or after starting varenicline set a date to quit smoking between days 8 and 35 of treatment. If patient has early lapses after quit day, encourage him/her to continue the attempt
Pregnancy Category:C
Breastfeeding: Safety unknown. Manufacturer recommends discontinuation of either the drug or of breastfeeding (taking into consideration the importance of drug to the mother).
Pricing data from www.DrugStore.com in U.S.A.
- Chantix 0.5 MG TABS [Bottle] (PFIZER U.S.)
56 mg = $177.65
168 mg = $499.17 - Chantix Continuing Month Pak 1 MG TABS [Box] (PFIZER U.S.)
56 mg = $176.99
168 mg = $483.97 - Chantix 1 MG TABS [Bottle] (PFIZER U.S.)
56 mg = $179
168 mg = $506.96
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Chantix 0.5 MG Oral Tablet
Ingredient(s): Varenicline
Imprint: Pfizer;CHX;0;5
Color(s): White
Shape: Oval
Size (mm): 8.00
Score: 1
Inactive Ingredient(s): cellulose, microcrystalline / anhydrous dibasic calcium phosphate / croscarmellose sodium / silicon dioxide / magnesium stearate
Drug Label Author:
Pfizer Laboratories Div Pfizer Inc
DEA Schedule:
Non-Scheduled
Drug Name: Chantix Continuing Months Of Therapy Pack
Ingredient(s): Varenicline
Imprint: Pfizer;CHX;1;0
Color(s): Blue
Shape: Oval
Size (mm): 10.00
Score: 1
Inactive Ingredient(s): cellulose, microcrystalline / anhydrous dibasic calcium phosphate / croscarmellose sodium / silicon dioxide / magnesium stearate
Drug Label Author:
Pfizer Laboratories Div Pfizer Inc
DEA Schedule:
Non-Scheduled
